2751530-13-7
2751530-13-7 結(jié)構(gòu)式
| 報價日期 | 產(chǎn)品編號 | 產(chǎn)品名稱 | CAS號 | 包裝 | 價格 |
| 2025/12/22 | HY-19522A | Seladelpar sodium salt | 2751530-13-7 | 1 mg | 210元 |
| 2025/12/22 | HY-19522A | Seladelpar sodium salt Seladelpar sodium salt | 2751530-13-7 | 5mg | 480元 |
| 2025/12/22 | HY-19522A | Seladelpar sodium salt Seladelpar sodium salt | 2751530-13-7 | 10mM * 1mLin DMSO | 528元 |
常見問題列表
|
PPAR-δ 2 nM (EC 50 ) |
MBX-8025 is an orally active, potent (EC 50 =2 nM), and specific (750-fold and 2500-fold compared with PPARα or PPARγ receptors, respectively) PPARδ agonist being developed as a lipid-altering agent.
In atherogenic diet-fed Wt mice, administration of Seladelpar sodium salt reduces body weight by ~18% (P<0.05). In contrast, Seladelpar sodium salt produces minimal effect on body weight in atherogenic diet-fed foz/foz mice. Seladelpar sodium salt lowers serum alanine aminotransferase (ALT) levels in foz/foz mice (P<0.05) and similarly (but not significantly) in Wt mice. Seladelpar sodium salt normalizes serum cholesterol and decreases triglycerides in both genotypes (P<0.05). Seladelpar sodium salt abolishes hepatocyte ballooning (P<0.05) and decreases the nonalcoholic fatty liver disease (NAFLD) activity score by ~50%. Seladelpar sodium salt also significantly reduces sirius red-positive areas in foz/foz mice (P<0.05).